# Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

> **NCT02601573** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 101 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Elbasvir
- **DRUG:** Ribavirin
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT02601573
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-05
- **Primary completion:** 2016-10-18
- **Final completion:** 2017-01-06
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601573, "Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02601573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*